BRAF and neoplasm: Of these, over 90% of the BRAF mutations are a missense mutation resulting in the substitution of valine for glutamic acid at codon 600.41 Early detection of melanoma and tumor-typing for the BRAF-V600E mutation can then inform therapeutic options, such as treatment with vemurafenib or dabrafenib which specifically target the activating mutation.42